LIFEVANTAGE CORP Operating Lease, Payments
LIFEVANTAGE CORP (LFVN) reported Operating Lease, Payments of $2.19 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-27.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-08-27
- LIFEVANTAGE CORP operating lease, payments for the quarter ending 2026-06-30 was $548.00K, a 5.68% decline year-over-year.
- LIFEVANTAGE CORP operating lease, payments for the quarter ending 2026-03-31 was $551.00K, a 3.84% decline year-over-year.
- LIFEVANTAGE CORP operating lease, payments for the quarter ending 2025-12-31 was $542.00K, a 3.90% decline year-over-year.
- LIFEVANTAGE CORP operating lease, payments for the quarter ending 2025-09-30 was $546.00K, a 3.02% increase year-over-year.
- LIFEVANTAGE CORP operating lease, payments for fiscal 2026 was $2.19M, a 4.25% decline from fiscal 2025.
- LIFEVANTAGE CORP operating lease, payments for fiscal 2025 was $2.28M, a 4.44% increase from fiscal 2024.
- LIFEVANTAGE CORP operating lease, payments for fiscal 2024 was $2.19M, a 26.44% decline from fiscal 2023.
- LIFEVANTAGE CORP operating lease, payments for fiscal 2023 was $2.97M, a 9.75% increase from fiscal 2022.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 3 month as first filed | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $548.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-27 | $1.10M derived: sum of 2 quarters · filed 2026-08-27 | $1.64M derived: sum of 3 quarters · filed 2026-08-27 | $2.19M 10-K · filed 2026-08-27 | |
| 2026-03-31 | $551.00K 10-Q · filed 2026-05-06 | $1.09M derived: sum of 2 quarters · filed 2026-05-06 | $1.64M 10-Q · filed 2026-05-06 | $2.22M derived: sum of 4 quarters · filed 2026-08-27 | |
| 2025-12-31 | $542.00K 10-Q · filed 2026-02-04 | $1.09M 10-Q · filed 2026-02-04 | $1.67M derived: sum of 3 quarters · filed 2026-08-27 | $2.24M derived: sum of 4 quarters · filed 2026-08-27 | |
| 2025-09-30 | $546.00K 10-Q · filed 2025-11-04 | $1.13M derived: sum of 2 quarters · filed 2026-08-27 | $1.70M derived: sum of 3 quarters · filed 2026-08-27 | $2.26M derived: sum of 4 quarters · filed 2026-08-27 | |
| 2025-06-30 | $581.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-27 | $1.15M derived: sum of 2 quarters · filed 2026-08-27 | $1.72M derived: sum of 3 quarters · filed 2026-08-27 | $2.28M 10-K · filed 2026-08-27 | |
| 2025-03-31 | $573.00K 10-Q · filed 2026-05-06 | $1.14M derived: sum of 2 quarters · filed 2026-05-06 | $1.70M 10-Q · filed 2026-05-06 | $2.20M derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-12-31 | $564.00K 10-Q · filed 2026-02-04 | $1.13M 10-Q · filed 2026-02-04 | $1.63M derived: sum of 3 quarters · filed 2026-02-04 | $2.19M derived: sum of 4 quarters · filed 2026-02-04 | |
| 2024-09-30 | $530.00K 10-Q · filed 2025-11-04 | $1.07M derived: sum of 2 quarters · filed 2025-11-04 | $1.63M derived: sum of 3 quarters · filed 2025-11-04 | $2.38M derived: sum of 4 quarters · filed 2025-11-04 | |
| 2024-06-30 | $536.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-04 | $1.10M derived: sum of 2 quarters · filed 2025-09-04 | $1.85M derived: sum of 3 quarters · filed 2025-09-04 | $2.19M 10-K · filed 2025-09-04 | |
| 2024-03-31 | $560.00K 10-Q · filed 2025-05-06 | $1.31M derived: sum of 2 quarters · filed 2025-05-06 | $1.65M 10-Q · filed 2025-05-06 | $2.56M derived: sum of 4 quarters · filed 2025-05-06 | |
| 2023-12-31 | $755.00K 10-Q · filed 2025-02-05 | $533.00K 10-Q · filed 2024-01-30 | $1.09M 10-Q · filed 2025-02-05 | $2.00M derived: sum of 3 quarters · filed 2025-02-05 | $2.78M derived: sum of 4 quarters · filed 2025-02-05 |
| 2023-09-30 | $557.00K 10-Q · filed 2024-10-29 | $1.24M derived: sum of 2 quarters · filed 2024-10-29 | $2.02M derived: sum of 3 quarters · filed 2024-10-29 | $2.78M derived: sum of 4 quarters · filed 2024-10-29 | |
| 2023-06-30 | $685.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-08-28 | $1.47M derived: sum of 2 quarters · filed 2024-08-28 | $2.22M derived: sum of 3 quarters · filed 2024-08-28 | $2.97M 10-K · filed 2024-08-28 | |
| 2023-03-31 | $782.00K 10-Q · filed 2024-05-02 | $1.54M derived: sum of 2 quarters · filed 2024-05-02 | $2.29M 10-Q · filed 2024-05-02 | $3.14M derived: sum of 4 quarters · filed 2024-05-02 | |
| 2022-12-31 | $755.00K 10-Q · filed 2024-01-30 | $1.51M 10-Q · filed 2024-01-30 | $2.36M derived: sum of 3 quarters · filed 2024-01-30 | $3.17M derived: sum of 4 quarters · filed 2024-01-30 | |
| 2022-09-30 | $755.00K 10-Q · filed 2023-11-09 | $1.61M derived: sum of 2 quarters · filed 2023-11-09 | $2.41M derived: sum of 3 quarters · filed 2023-11-09 | $2.93M derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-06-30 | $851.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-08-28 | $1.66M derived: sum of 2 quarters · filed 2023-08-28 | $2.18M derived: sum of 3 quarters · filed 2023-08-28 | $2.71M 10-K · filed 2023-08-28 | |
| 2022-03-31 | $804.00K 10-Q · filed 2023-05-04 | $1.33M derived: sum of 2 quarters · filed 2023-05-04 | $1.86M 10-Q · filed 2023-05-04 | $2.60M derived: sum of 4 quarters · filed 2023-05-04 | |
| 2021-12-31 | $524.00K 10-Q · filed 2023-02-02 | $1.05M 10-Q · filed 2023-02-02 | $1.79M derived: sum of 3 quarters · filed 2023-02-02 | $2.44M derived: sum of 4 quarters · filed 2023-02-02 | |
| 2021-09-30 | $768.00K 10-Q · filed 2022-11-02 | $1.27M derived: sum of 2 quarters · filed 2022-11-02 | $1.91M derived: sum of 3 quarters · filed 2022-11-02 | $2.69M derived: sum of 4 quarters · filed 2022-11-02 | |
| 2021-06-30 | $499.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-08-23 | $1.14M derived: sum of 2 quarters · filed 2022-08-23 | $1.92M derived: sum of 3 quarters · filed 2022-08-23 | $2.54M 10-K · filed 2022-08-23 | |
| 2021-03-31 | $645.00K 10-Q · filed 2022-05-03 | $1.42M derived: sum of 2 quarters · filed 2022-05-03 | $2.04M 10-Q · filed 2022-05-03 | $2.77M derived: sum of 4 quarters · filed 2022-05-03 | |
| 2020-12-31 | $776.00K 10-Q · filed 2022-02-01 | $1.39M 10-Q · filed 2022-02-01 | $2.12M derived: sum of 3 quarters · filed 2022-02-01 | $2.84M derived: sum of 4 quarters · filed 2022-02-01 | |
| 2020-09-30 | $616.00K 10-Q · filed 2021-11-04 | $1.35M derived: sum of 2 quarters · filed 2021-11-04 | $2.06M derived: sum of 3 quarters · filed 2021-11-04 | $2.78M derived: sum of 4 quarters · filed 2021-11-04 | |
| 2020-06-30 | $730.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-08-19 | $1.45M derived: sum of 2 quarters · filed 2021-08-19 | $2.17M derived: sum of 3 quarters · filed 2021-08-19 | $2.89M 10-K · filed 2021-08-19 | |
| 2020-03-31 | $716.00K 10-Q · filed 2021-04-29 | $1.44M derived: sum of 2 quarters · filed 2021-04-29 | $2.16M 10-Q · filed 2021-04-29 | ||
| 2019-12-31 | $720.00K 10-Q · filed 2021-02-02 | $1.44M 10-Q · filed 2021-02-02 | |||
| 2019-09-30 | $720.00K 10-Q · filed 2020-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |